CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-17 | Cummings James F. Chief Medical Officer | Grant or award | +59,350 | 148,100 | ||
| 2023-03-17 | Cummings James F. Chief Medical Officer | Grant or award | +90,000 | 238,100 | ||
| 2023-03-17 | Cummings James F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +205,000 | 205,000 | ||
| 2023-03-17 | Cummings James F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2022-12-28 | Watson W. Mark Director | Purchase | +20,000 | $0.76 | $15K | 20,000 |
| 2022-12-16 | Lee Phillip E Chief Financial Officer | Grant or award | +68,750 | 68,750 | ||
| 2022-12-16 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +412,500 | 412,500 | ||
| 2022-08-25 | HERON ELAINE J Director | Grant or award | +14,750 | 17,644 | ||
| 2022-08-25 | HERON ELAINE J Director | Grant or award · Stock Option (right to buy) | +88,448 | 88,448 | ||
| 2022-08-24 | Yedid Robert A. Director | Gift | −18,240 | 19,115 | ||
| 2022-08-24 | Yedid Robert A. Director | Gift | −4,000 | 15,115 | ||
| 2022-08-24 | Yedid Robert A. Director | Gift | −4,000 | 11,115 | ||
| 2022-08-19 | Yedid Robert A. Director | Option exercise | +18,240 | $0.31 | $6K | 29,355 |
| 2022-08-19 | Yedid Robert A. Director | Option exercise | +8,000 | $2.39 | $19K | 37,355 |
| 2022-08-19 | Yedid Robert A. Director | Option exercise · Stock Option (right to buy) | −18,240 | 18,240 | ||
| 2022-08-19 | Yedid Robert A. Director | Option exercise · Stock Option (right to buy) | −8,000 | 57,700 | ||
| 2022-08-04 | Watson W. Mark Director | Grant or award | +14,750 | 14,750 | ||
| 2022-08-04 | Watson W. Mark Director | Grant or award · Stock Option (right to buy) | +88,448 | 88,448 | ||
| 2022-08-04 | Yedid Robert A. Director | Grant or award | +7,375 | 11,115 | ||
| 2022-08-04 | Yedid Robert A. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 |
Page 9 of 10 · 198 trades